Concurrently, EVs in patients with cardiovascular disease significantly inhibit in vivo activation of endothelial nitric oxide synthase (eNOS), the bioavailability of nitric oxide (NO), and tissue plasminogen activator (t-PA) production, which promotes atherosclerosis and thrombosis [43]. This evidence concerns the gene PLAT and cardiovascular disorder.